# What does “research use only” mean on a peptide?

> The label is a seller’s statement that a product is for laboratory research, not people: such a product has had no FDA review and is sold without a prescription. The FDA treats research-labeled peptides as unapproved drugs when they are sold for human use, and small lab studies of peptides bought online found wrong amounts and impurities.

The journal is published by Rovere, a telehealth service that sells some of the treatments discussed here. Articles are general information, not medical advice. Only a licensed clinician can say whether a treatment is right for you.

- Topic: Safety
- Web page: https://roverehealth.com/journal/research-use-only-peptides

## Key points

- A “research use only” label is a seller’s statement that a product is not for people. Peptides sold this way are not FDA-approved products, have had no FDA review of their safety or quality, and come without a prescription.
- The FDA judges a product by its intended use, not its disclaimer. In warning letters dated February 2024 to August 2026, it called sellers’ research-labeled peptides unapproved drugs, citing health claims, water sold for mixing injections and a peptide calculator.
- In a 2024 study, all three semaglutide vials bought online without a prescription held more drug than their labels stated and were mostly material other than semaglutide. One had a level of bacterial toxins (endotoxins) the authors called elevated.
- Injected products bypass some of the body’s defenses against microbes and toxins. A product can be free of live bacteria and still contain endotoxins, which at high levels can cause fever, low blood pressure and death, the FDA says.
- Serious reactions and quality problems with a drug, including a research-labeled peptide, can be reported to the FDA’s MedWatch program. Websites selling drugs illegally can be reported through a separate FDA form.

A “research use only” or “not for human consumption” label is a seller’s statement that a product is meant for laboratory experiments, not for people. When such peptides are sold for use in people, the FDA treats them as unapproved drugs that are illegal to sell. It calls research-labeled GLP-1 drugs, a class of diabetes and weight-loss medicines that includes semaglutide, “of unknown quality” and urges consumers not to buy them. [1, 2, 3]

## What the label means

In the FDA’s regulations, the words “For Research Use Only” appear in the labeling rules for laboratory diagnostic tests that are still in the research phase. There, they are followed by “Not for use in diagnostic procedures.” [4]

A separate rule covers drugs, and it does not use that phrase. It lets a company ship an unapproved drug meant only for laboratory tests, in test tubes (in vitro) or in research animals, on conditions that include these: [5]

- The label must say the drug is for investigational use only in laboratory research animals or for tests in vitro, and “Not for use in humans.”
- The shipper must take care that the buyer regularly runs such tests and will actually use the drug for them.

Sources for the list above: [5]

A second rule frees prescription drugs from carrying directions for use only when they go to people regularly and lawfully doing work such as research, teaching or testing. That work must not involve giving the drugs to people. Neither rule covers sales to the public. [6]

The FDA says research-labeled GLP-1 drugs have been sold straight to consumers, with dosing instructions. Sold that way, they skip the checks that apply to FDA-approved medicines: [1]

- No FDA review. Without it, the FDA says, there is no way to know whether a drug is safe and works, is made to consistent quality, or has a complete and accurate label. Compounded (custom-mixed) medicines do not get this review either.
- No prescription. Federal law allows prescription drugs to be dispensed only on a licensed practitioner’s prescription. In 2025 the FDA told an online seller that offering semaglutide and tirzepatide without one broke that law.
- No approval for the product. Semaglutide and tirzepatide are ingredients in FDA-approved medicines, but the FDA found that no approval covered that seller’s research-labeled versions.
- For some, no approved version at all. Retatrutide, an experimental drug that one seller offered as “Research Use Only,” is not part of any FDA-approved medicine, and federal law bars its use in compounding.

Sources for the list above: [1, 2, 3, 7, 8, 9, 10]

The genuine ingredients have risks of their own. FDA-approved semaglutide and tirzepatide carry a boxed warning about thyroid tumors seen in rodents, along with other label warnings that the journal’s GLP-1 article covers. [11, 12]

## How the FDA treats research-labeled peptides

Whether a product is a drug depends on its intended use, which a disclaimer does not settle. Federal rules define intended use as the seller’s objective intent, shown by labeling, advertising, statements and the circumstances of the sale. [3, 13]

A warning letter is the FDA’s written notice of violations. Failing to fix them may lead to seizure of products or a court order (an injunction). In warning letters to four online peptide sellers, dated February 2024 to August 2026, the FDA rejected their research-use disclaimers. Each seller’s website, the letters say, shows the products are intended as drugs for people. [2, 3, 14, 15]

- Product-page claims about weight loss or blood sugar control counted as evidence.
- So did bacteriostatic water for dissolving peptide powder, sold on the same site. The FDA treated the water itself as a drug meant for injection.
- One seller also offered insulin syringes.
- Another sold the water alongside an online “peptide guide” and “peptide calculator,” which the FDA said “collectively provide the means to prepare an injectable drug for human administration.”

Sources for the list above: [2, 3, 14, 15]

Other FDA warnings went to sellers of research-labeled retatrutide, survodutide and mazdutide, GLP-1 drugs not approved in the US. An August 2026 letter named tesamorelin, bremelanotide (sold as PT-141) and elamipretide (SS-31), finding no approval for that seller’s versions. Each is the active ingredient of an FDA-approved medicine with one narrow use. Tesamorelin is approved to reduce excess abdominal fat in some adults with HIV, and bremelanotide for a form of low sexual desire in women before menopause. Elamipretide has accelerated approval, which a further trial may need to confirm, to improve muscle strength in Barth syndrome, a rare inherited disease. [1, 15, 16, 17, 18]

In October 2026 the FDA’s parent department, Health and Human Services (HHS), published a nonbinding draft policy on drugs compounded from six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound these peptides for individual patients under its conditions. It says the policy will discourage the widespread use of certain research-use-only peptides from foreign manufacturers that pose a safety risk to US patients. The policy is not an FDA approval and does not cover products sold for research use. [37, 38]

## What testing has found

In a 2024 study, researchers in Hungary and the US ordered semaglutide without a prescription from six websites selling it illegally. Three orders, all for prefilled pens, were scams and never arrived. The three vials that did arrive were presented as laboratory products, some labeled “research use only,” while the sellers’ pages described benefits such as weight loss. No vial seller asked for proof that the buyer was a researcher. [9]

- All three vials contained semaglutide and no peptide-like impurities, but each held more than its label stated, about a third more on average. The authors warned this could lead to incorrect dosing or overdose.
- Sellers claimed near-total purity, a research-grade claim that the authors said differs from pharmaceutical quality. Semaglutide made up less than a sixth of each powder’s weight, and the authors could not identify the rest.
- One vial held endotoxin, a toxic remnant of certain bacteria, at a level the authors called elevated. The paper’s results report the other two only as below a cutoff, though its summary says all three contained some. The paper does not compare any result with an endotoxin limit for injectable drugs. No live microbes were found in any vial.

Sources for the list above: [9, 19]

What three other laboratory studies found in peptides sold outside regulated pharmacies. [20, 21, 22]

| Study | What was tested | What the lab found |
| --- | --- | --- |
| Melanotan II, 2015 | Vials of an injectable tanning peptide from three online shops | Every vial held less than its label claimed, the lowest less than half. Vials from two shops held unidentified impurities. |
| Falsified peptide drugs in Belgium, 2018 | Ten common falsified peptide drugs from three suspected illegal online pharmacies | Amounts per unit varied widely, and purity was low in some. Several held arsenic at up to ten times the international safety limit for injected drugs, and one held lead. |
| Products sold as retatrutide in Australia, 2026 | Three products labeled as retatrutide, submitted anonymously to a drug-checking service | All held retatrutide: one about half the labeled amount, two well over it, up to almost twice. Metal impurities were low. Sterility and endotoxin were not tested. |

These studies are small, and the semaglutide authors called their few test purchases a major limitation. How often research-labeled peptides sold in the US today are contaminated or mislabeled is not known. [9, 20, 21, 22]

## Reports of harm

The FDA’s May 2026 review of BPC-157, prepared for a July advisory committee meeting, describes a 40-year-old woman. She injected a product labeled for “research purposes only” that contained two peptides, BPC-157 and TB-500. After a week of use her skin and gums darkened, and the same reaction returned when she used it again. The FDA judged it likely due to the product but could not tell which peptide was responsible. [23]

For melanotan II, the FDA cites published case reports of melanoma, a skin cancer; a brain disorder (posterior reversible encephalopathy syndrome); stimulant-like poisoning; and prolonged, painful erections. [24]

In 2026, doctors in Zurich reported a woman in her mid-20s admitted with persistent vomiting after four weekly injections of a product said to contain retatrutide. She mentioned the injections only after repeated, non-judgmental questioning, because she had not thought of them as medication. On a standard scale for judging drug reactions, the doctors rated the injections a probable cause but could not confirm it, because the product was never tested. [25]

A doctor in Edinburgh reported a man with type 1 diabetes who dissolved and injected a powder labeled “not for human or veterinary consumption” that he had bought online as retatrutide. He began vomiting within hours, skipped his insulin and was admitted with kidney injury and a dangerous build-up of ketones, which form when the body lacks insulin. His partner injected the same product and also had stomach symptoms. But both had eaten poorly thawed chicken soup, and his stool grew Shigella bacteria. The author could not establish the cause but thought the product may have worsened the illness. [26]

Both case reports urge clinicians to ask patients directly about peptides and research chemicals. [25, 26]

## Why injections carry extra risk

Injectable products “bypass some of the body’s key defenses against toxins and microorganisms,” the FDA wrote in a March 2026 warning letter. A 2025 letter named bloodstream infection and sepsis, a life-threatening reaction to infection. A product can be sterile, meaning free of living microbes, and still contain endotoxin, as one vial in the 2024 semaglutide study did. [2, 3, 9]

In August 2026 the FDA reported at least 30 patients with reactions, including fever, signs of shock and sepsis-like symptoms, after glutathione was given into a vein. Some were hospitalized. The FDA said the symptoms fit excess endotoxin, which can also cause low blood pressure and death. Compounding pharmacies had made the drugs from glutathione labeled dietary supplement grade, which the FDA says is unsuitable for injectable drugs. [27]

A passing sterility test does not prove a product is sterile, because contamination is not spread evenly through a batch, says the FDA’s 2020 guidance on compounding. The agency tells compounders to build quality into every step rather than rely on testing alone. [27, 28]

The immune system can also react to an injected peptide (immunogenicity). The FDA has flagged this risk for BPC-157, TB-500, MOTS-c, melanotan II and other peptides proposed for compounding. Clumps of peptide molecules and near-copies left over from manufacturing raise it, and injection under the skin may strengthen it. Reactions can range from antibodies that cause no symptoms to life-threatening ones, the FDA says. [23, 24]

In a 2026 University of Connecticut study, 20 adults were given semaglutide, a liquid to dissolve it and injection supplies, with only online information to guide them. On average they completed 15 of 34 required steps correctly, with errors that could cause wrong doses, needle-stick injuries or infections. [29]

## Importing peptides

It is usually illegal for individuals to import drugs for personal use, the FDA says, even drugs approved abroad but not in the US. Since 2016 the agency has been able to destroy refused drug shipments worth $2,500 or less that arrive by mail or express courier, without sending them back. [30, 31]

FDA import alerts let border staff hold listed products without examining them. One alert, for unapproved new drugs promoted in the US, lists peptide products. Its earliest entries for melanotan, from 2010, say it was imported as being for non-human research, then sold online as an unapproved drug. [7]

From December 2025 to March 2026, customs officers in Cincinnati seized about 5,000 peptide shipments from a shipper in China, U.S. Customs and Border Protection said. They were hidden in more than 300 falsely declared cartons and included retatrutide, semaglutide, tirzepatide, MOTS-c and cagrilintide. Like retatrutide, cagrilintide is not part of any FDA-approved medicine and cannot legally be used in compounding. [1, 32]

## Rules for athletes

The World Anti-Doping Agency bans at all times any substance not covered elsewhere on its list that no government health regulator has approved as a medicine for people. It names BPC-157 as an example, and its 2027 list, in force from January 1, 2027, adds peptides to the examples. [33, 34]

## How to report a problem

Serious reactions and quality problems with any drug, including a research-labeled peptide, can be reported to the FDA’s MedWatch program, online or by phone. A separate FDA form takes reports of websites that seem to sell drugs illegally, and the journal’s license-checking article gives the details. [35, 36]

## Sources

1. FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
2. FDA. Warning letter 696885 on semaglutide and tirzepatide sold online as research products. 2025. Regulator. Checked 2026-11-13. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usapeptidecom-696885-02262025
3. FDA. Warning letter 721806 on retatrutide, tirzepatide and bacteriostatic water sold online for research use. 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
4. Code of Federal Regulations. 21 CFR 809.10, Labeling for in vitro diagnostic products. Regulator. Checked 2026-11-13. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-809/subpart-B/section-809.10
5. Code of Federal Regulations. 21 CFR 312.160, Drugs for investigational use in laboratory research animals or in vitro tests. Regulator. Checked 2026-11-13. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-G/section-312.160
6. Code of Federal Regulations. 21 CFR 201.125, Drugs for use in teaching, law enforcement, research, and analysis. Regulator. Checked 2026-11-13. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-D/section-201.125
7. FDA. Import Alert 66-41: Detention Without Physical Examination of Unapproved New Drugs Promoted in the U.S. 2026. Regulator. Checked 2026-11-13. https://www.accessdata.fda.gov/cms_ia/importalert_190.html
8. Belcourt J et al. Bypassing prescribers and pharmacists: online purchasing of semaglutide and tirzepatide “for research purposes”. Ann Pharmacother. 2025. Reference. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/39285774/
9. Ashraf AR et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: market surveillance, content analysis, and product purchase evaluation study. J Med Internet Res. 2024. Lab study. Checked 2026-11-13. https://doi.org/10.2196/65440
10. FDA. Compounding and the FDA: Questions and Answers. 2025. Regulator. Checked 2026-11-13. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
11. FDA-approved semaglutide injection and tablets for weight management: prescribing information (DailyMed). 2026. Regulator. Checked 2026-11-13. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
12. FDA-approved tirzepatide injection for weight management: prescribing information (DailyMed). 2026. Regulator. Checked 2026-11-13. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
13. Code of Federal Regulations. 21 CFR 201.128, Meaning of “intended uses”. Regulator. Checked 2026-11-13. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-D/section-201.128
14. FDA. Warning letter 669074 on semaglutide, tirzepatide and thymalin sold online as research chemicals. 2024. Regulator. Checked 2026-11-13. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-chem-labs-669074-02072024
15. FDA. Warning letter 734884 on GLP-1 and other peptides sold online for research use. 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026
16. National Library of Medicine, DailyMed. Tesamorelin for injection, single-dose vial: FDA-approved prescribing information (revised March 2024). 2024. Regulator. Checked 2026-11-13. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
17. FDA-approved bremelanotide injection: prescribing information (DailyMed). 2026. Regulator. Checked 2026-11-13. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
18. National Library of Medicine, DailyMed. Elamipretide injection: FDA-approved prescribing information (September 2025). 2025. Regulator. Checked 2026-11-13. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75
19. Ashraf AR et al. Safety and risk assessment of no-prescription online semaglutide purchases. JAMA Netw Open. 2024. Lab study. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/39093567/
20. Breindahl T et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015. Lab study. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/24771717/
21. Janvier S et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018. Lab study. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/30029448/
22. Piatkowski T et al. Composition and labelling accuracy of products sold as retatrutide in Australia. Drug Alcohol Rev. 2026. Lab study. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/42559975/
23. FDA. Briefing document: BPC-157-related bulk drug substances. Pharmacy Compounding Advisory Committee, July 23 and 24, 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/media/193343/download
24. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
25. Buzzi RM, Huber LC. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide (case report). BMJ Case Rep. 2026. Observational study in people. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/42843917/
26. Branine N. Online-sourced retatrutide complicating impending diabetic ketoacidosis in a patient with type 1 diabetes and concurrent Shigella gastroenteritis (case report). Cureus. 2026. Observational study in people. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/42669023/
27. FDA. FDA reminds compounders not to use dietary supplement grade glutathione for injectables. 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-not-use-dietary-supplement-grade-glutathione-injectables
28. FDA. Insanitary Conditions at Compounding Facilities: Guidance for Industry. 2020. Regulator. Checked 2026-11-13. https://www.fda.gov/media/124948/download
29. Sedensky A et al. Ability of adults to correctly use grey market peptide semaglutide GLP-1 receptor agonists acquired without a prescription. Public Health Rep. 2026. Observational study in people. Checked 2026-11-13. https://pubmed.ncbi.nlm.nih.gov/42541373/
30. FDA. Personal Importation. 2025. Regulator. Checked 2026-11-13. https://www.fda.gov/industry/import-basics/personal-importation
31. FDA. Administrative Destruction Authority. 2026. Regulator. Checked 2026-11-13. https://www.fda.gov/industry/import-basics/administrative-destruction-authority
32. U.S. Customs and Border Protection. Cincinnati CBP foils scheme to smuggle over 5,000 unapproved peptides into the U.S. 2026. Regulator. Checked 2026-11-13. https://www.cbp.gov/newsroom/local-media-release/cincinnati-cbp-foils-scheme-smuggle-over-5000-unapproved-peptides-us
33. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. 2025. Regulator. Checked 2026-11-13. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
34. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. 2026. Regulator. Checked 2026-11-13. https://www.wada-ama.org/sites/default/files/2026-11/2027list_en_final_clean_4_nov_2026.pdf
35. FDA. Reporting Serious Problems to FDA (MedWatch). 2025. Regulator. Checked 2026-11-13. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda
36. FDA. Ways for Consumers to Contact FDA about Human Drugs. 2024. Regulator. Checked 2026-11-13. https://www.fda.gov/about-fda/cder-contact-information/ways-consumers-contact-fda-about-human-drugs
37. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (draft, revised November 6, 2026). 2026. Regulator. Checked 2026-11-14. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
38. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526. 2026. Regulator. Checked 2026-11-14. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances

## Related articles

- [What to check when a compounded injection arrives](https://roverehealth.com/journal/checking-a-compounded-injection.md): Check that the package is intact and cold if required, that the label names the pharmacy, patient, drug, strength and a use-by date, and that you know how to measure the dose. Compounded drugs are not FDA-approved, and these checks cannot show whether one is sterile or as strong as its label says.
- [What are BPC-157 and TB-500?](https://roverehealth.com/journal/bpc-157-and-tb-500.md): BPC-157 and TB-500 are lab-made peptides promoted for healing injuries: BPC-157 copies part of a protein reported in stomach juice, and TB-500 copies a fragment of thymosin beta-4, which the body makes. Neither is FDA-approved, and research on healing is almost all in animals, with no completed controlled trial for an injury in people.
- [What are GLP-1 medications like semaglutide and tirzepatide?](https://roverehealth.com/journal/glp-1-medications.md): GLP-1 medications mimic a gut hormone that helps control blood sugar and appetite; after large trials, the FDA approved semaglutide and tirzepatide products for type 2 diabetes, weight management and other uses. Digestive side effects are common and weight tends to return after stopping; compounded versions are not FDA-approved and were not tested in those trials.
- [How to check a pharmacy or clinician license](https://roverehealth.com/journal/how-to-check-a-pharmacy-or-clinician-license.md): Check a pharmacy with the board of pharmacy in your state and in its home state, as the FDA advises, and a prescriber with your state’s board for their profession. A license is permission to practice, not FDA approval: compounded drugs are not FDA-approved, and the FDA does not approve or license any pharmacy.